[Changes in the central hemodynamics during the treatment of hypertension with Renitec and its combination with...

Overall sixty patients with hypertensive disease were examined for clinical effectiveness of the prolonged-action inhibitor angiotensine-converting enzyme renitek (enalapril maleate, MJD). The treatment schedule included placebo over two weeks, renitek as monotherapy, 20 mg daily, over 6 weeks, if the patients failed to derive any benefit from the therapy, they were placed on a 4-week combined therapy of renitek plus hydrochlorothiazide. Renitek was found to dispel cardialgias, reduce frequency of attacks of cardiac angina. In the hemodynamic structure, a positive inotropic effect was identified as was reduction of energy expenditure of the myocardium, total peripheral vascular resistance, diminution of post- and preloads on the myocardium, with the mass of the left ventricular myocardium growing less.